Drug intelligence / Profile preview

SPR4

Development stage: Preclinical
Lead developer: Sporos BioDiscovery
Modality: Small Molecules

Overview

SPR4 is a preclinical small molecule therapeutic being developed by Sporos BioDiscovery for the treatment of PTEN-deficient cancers. While the specific molecular target remains undisclosed, the drug is designed to target a pathway associated with PTEN deficiency. Its mechanism of action involves reversing immunosuppression within the tumor microenvironment, which may provide synergistic effects when combined with immune checkpoint inhibitors. The compound is currently in the preclinical stage of development as part of a precision oncology pipeline.

Beyond the preview

Go deeper on SPR4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPR4.

Explore the full profile